Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€10.10

€10.10

-
-
-
-
 
13.07.23 / Tradegate WKN: A2JK4Q / Name: Polyphor / Stock / ? / We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Financial data and news for Polyphor

sharewise wants to provide you with the best news and tools for Polyphor, so we directly link to the best financial data sources.

News

Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024. 
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024. 
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024. 
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Spexis announces closing of sale of preclinical antibiotics program to Basilea
Spexis announces closing of sale of preclinical antibiotics program to Basilea
Spexis announces closing of sale of preclinical antibiotics program to Basilea
Spexis announces sale of preclinical antibiotics program to Basilea
Spexis announces sale of preclinical antibiotics program to Basilea
Spexis announces sale of preclinical antibiotics program to Basilea
 Spexis is Granted Debt-Restructuring Moratorium
Spexis is Granted Debt-Restructuring Moratorium
Spexis is Granted Debt-Restructuring Moratorium
Spexis Provides Update Regarding Debt-Restructuring Moratorium
Spexis Provides Update Regarding Debt-Restructuring Moratorium
Spexis Provides Update Regarding Debt-Restructuring Moratorium